ATE359787T1 - Kontrollierte synthese von ziprasidon - Google Patents

Kontrollierte synthese von ziprasidon

Info

Publication number: ATE359787T1
Authority: AT; Austria
Prior art keywords: ziprasidone; controlled synthesis; synthesis; controlled
Prior art date: 2002-02-20

Application number

AT03702918T

Other languages

English (en)

Inventor

Frank Robert Busch

Adam Worth Grobin

Harry Ralph Howard Jr

Kyle Robert Leeman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-20

Filing date

2003-02-17

Publication date

2007-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE359787(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE359787T1 publication Critical patent/ATE359787T1/de

Links

230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title 1
229960000607 ziprasidone Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Liquid Crystal Substances (AREA)
Indole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

AT03702918T 2002-02-20 2003-02-17 Kontrollierte synthese von ziprasidon ATE359787T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US35880602P	2002-02-20	2002-02-20
US35903802P	2002-02-21	2002-02-21
US36045902P	2002-02-27	2002-02-27

Publications (1)

Publication Number	Publication Date
ATE359787T1 true ATE359787T1 (de)	2007-05-15

Family

ID=27761437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03702918T ATE359787T1 (de)	2002-02-20	2003-02-17	Kontrollierte synthese von ziprasidon

Country Status (41)

Country	Link
EP (1)	EP1476162B1 (de)
JP (1)	JP4554938B2 (de)
KR (1)	KR100773622B1 (de)
CN (2)	CN101735212A (de)
AP (1)	AP2004003103A0 (de)
AR (1)	AR038563A1 (de)
AT (1)	ATE359787T1 (de)
AU (2)	AU2003206035A1 (de)
BR (1)	BR0307833A (de)
CA (1)	CA2475302C (de)
CO (1)	CO5611138A2 (de)
CY (1)	CY1106467T1 (de)
DE (1)	DE60313289T2 (de)
DK (1)	DK1476162T3 (de)
EA (1)	EA007866B1 (de)
EC (1)	ECSP045239A (de)
ES (1)	ES2283745T3 (de)
GE (1)	GEP20074030B (de)
GT (1)	GT200300040A (de)
HR (1)	HRP20040711A2 (de)
IL (1)	IL163277A (de)
IS (1)	IS7344A (de)
MA (1)	MA27177A1 (de)
MX (1)	MXPA04006993A (de)
MY (1)	MY139523A (de)
NO (2)	NO20043902L (de)
NZ (1)	NZ534443A (de)
OA (1)	OA12774A (de)
PA (1)	PA8567001A1 (de)
PE (1)	PE20030942A1 (de)
PL (1)	PL372238A1 (de)
PT (1)	PT1476162E (de)
RS (1)	RS60404A (de)
SI (1)	SI1476162T1 (de)
SV (1)	SV2004001485A (de)
TN (1)	TNSN04159A1 (de)
TW (1)	TW200307546A (de)
UA (1)	UA77057C2 (de)
UY (1)	UY27668A1 (de)
WO (1)	WO2003070246A1 (de)
ZA (1)	ZA200406276B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2397981C (en)	2000-03-06	2010-12-21	Acadia Pharmaceuticals, Inc.	Azacyclic compounds for use in the treatment of serotonin related diseases
CN101050215A (zh)	2001-12-28	2007-10-10	阿卡蒂亚药品公司	作为单胺受体调节剂的螺氮杂环化合物
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
AU2003247615B2 (en)	2002-06-24	2007-08-09	Acadia Pharmaceuticals Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US7488729B2 (en)	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
RU2332401C2 (ru)	2003-01-16	2008-08-27	Акадиа Фармасьютикалз Инк.	Селективные обратные агонисты серотонин 2а/2с рецептора, применяемые в качестве лекарственных средств при нейродегенеративных заболеваниях
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
US20040242661A1 (en)	2003-03-17	2004-12-02	Igor Rukhman	Polymorphs of valsartan
US7378531B2 (en)	2003-04-21	2008-05-27	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
US20050043324A1 (en)	2003-06-03	2005-02-24	Tamas Koltai	Polymorphic forms of ziprasidone HCI and processes for their preparation
US7667037B2 (en)	2003-10-24	2010-02-23	Teva Pharmaceutical Industries Ltd.	Processes for preparation of ziprasidone
US20050197347A1 (en) *	2003-12-18	2005-09-08	Judith Aronhime	Polymorphic form B2 of ziprasidone base
ATE451367T1 (de)	2004-02-27	2009-12-15	Ranbaxy Lab Ltd	Verfahren zur herstellung von ziprasidon
CA2467538C (en)	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en)	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
BRPI0516063A (pt)	2004-09-27	2008-08-19	Acadia Pharm Inc	sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas
ES2250001B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Procedimiento para la preparacion de ziprasidona.
WO2006080025A1 (en) *	2005-01-27	2006-08-03	Hetero Drugs Limited	Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) *	2005-11-18	2007-05-19	Dipharma Spa	Procedimento per la preparazione di ziprasidone
CN100491375C (zh) *	2006-07-01	2009-05-27	浙江美诺华药物化学有限公司	一种齐拉西酮的制备方法
EP2134330B1 (de)	2007-03-19	2013-05-08	Acadia Pharmaceuticals Inc.	Kombinationen aus 5-ht2a-inversagonisten und -antagonisten mit antipsychotika
CN102234273B (zh) *	2010-04-21	2015-08-05	上海医药工业研究院	甲磺酸齐拉西酮半水合物及其制备方法
CN102234272A (zh) *	2010-04-21	2011-11-09	上海医药工业研究院	盐酸齐拉西酮半水合物的制备方法
DK3325444T3 (da)	2015-07-20	2021-10-04	Acadia Pharm Inc	Fremgangsmåder til fremstilling af n-(4-fluorbenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamid og dets tartratsalt og polymorf form c
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
WO2018118626A1 (en)	2016-12-20	2018-06-28	Acadia Pharmaceuticals Inc.	Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) *	2016-12-26	2018-07-03	四川科瑞德凯华制药有限公司	一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en)	2017-04-28	2021-10-05	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
US20210077479A1 (en)	2017-08-30	2021-03-18	Acadia Pharmaceuticals Inc.	Formulations of pimavanserin
CN112724066B (zh) *	2021-02-04	2022-10-21	海南鑫开源医药科技有限公司	一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
TR199800814T2 (xx)	1995-11-07	1998-07-21	Pfizer Inc.	3-(1-piperazinil)-1,2-Benzizotiazol haz�rlamak i�in i�lemler ve ara �r�nler.
TW491847B (en)	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
PL188164B1 (pl) *	1996-05-07	2004-12-31	Pfizer	Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active IP Right Cessation
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 EP EP03702918A patent/EP1476162B1/de not_active Revoked
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en active Application Filing
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-04 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DK1476162T3 (da)	2007-07-02
HRP20040711A2 (en)	2004-12-31
DE60313289T2 (de)	2007-12-27
DE60313289D1 (de)	2007-05-31
TW200307546A (en)	2003-12-16
PT1476162E (pt)	2007-06-25
UA77057C2 (en)	2006-10-16
CO5611138A2 (es)	2006-02-28
SV2004001485A (es)	2004-05-07
WO2003070246A1 (en)	2003-08-28
PL372238A1 (en)	2005-07-11
NO20043902L (no)	2004-09-17
BR0307833A (pt)	2004-12-07
MXPA04006993A (es)	2004-11-10
RS60404A (en)	2006-10-27
JP2005525347A (ja)	2005-08-25
CN1635892A (zh)	2005-07-06
CY1106467T1 (el)	2012-01-25
GEP20074030B (en)	2007-02-12
KR100773622B1 (ko)	2007-11-05
EP1476162B1 (de)	2007-04-18
SI1476162T1 (sl)	2007-08-31
AP2004003103A0 (en)	2004-09-30
CA2475302C (en)	2009-05-12
EA007866B1 (ru)	2007-02-27
OA12774A (en)	2006-07-04
AR038563A1 (es)	2005-01-19
GT200300040A (es)	2007-01-12
EA200400815A1 (ru)	2004-12-30
MY139523A (en)	2009-10-30
CA2475302A1 (en)	2003-08-28
IL163277A (en)	2010-05-31
KR20040086417A (ko)	2004-10-08
NZ534443A (en)	2007-07-27
PE20030942A1 (es)	2003-11-08
AU2009202008A1 (en)	2009-06-11
JP4554938B2 (ja)	2010-09-29
IS7344A (is)	2004-07-05
UY27668A1 (es)	2003-10-31
ECSP045239A (es)	2004-09-28
TNSN04159A1 (fr)	2007-03-12
CN101735212A (zh)	2010-06-16
ES2283745T3 (es)	2007-11-01
NO20100584L (no)	2004-09-17
MA27177A1 (fr)	2005-01-03
EP1476162A1 (de)	2004-11-17
AU2003206035A1 (en)	2003-09-09
PA8567001A1 (es)	2003-12-10
ZA200406276B (en)	2005-09-20

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1476162

Country of ref document: EP

Publication	Publication Date	Title
DE60313289D1 (de)	2007-05-31	Kontrollierte synthese von ziprasidon
ATE365169T1 (de)	2007-07-15	Regioselektive synthese von cci-779
DE60325025D1 (de)	2009-01-15	Modulatoren des vanilloidrezeptors
ATE339252T1 (de)	2006-10-15	Aktivierung von fischer-tropsch- trägerkatalysatoren
DE602004008303D1 (de)	2007-09-27	Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602006012450D1 (de)	2010-04-08	Exo- und diastereoselektive synthese von himbacin-analoga
DE602006021628D1 (de)	2011-06-09	Verbesserte synthese und zubereitungen von duloxetinsalzen
DE602004004287D1 (de)	2007-02-22	Selektive synthese von cf3-substituierten pyrimidinen
DE602004013990D1 (de)	2008-07-03	Ernen von spänen
DE502004011575D1 (de)	2010-10-07	Verwendung von Dioldimerfettsäureestern
ATE242750T1 (de)	2003-06-15	Synthese von kristallinen silicoaluminophosphaten
ATE390411T1 (de)	2008-04-15	Stereoselektive synthese von vitamin-d-analoga
DE60313173D1 (de)	2007-05-24	Synthese von purin-derivaten
DE602004004262D1 (de)	2007-02-22	Ultraschallbehandlung von gewebematrices
DE50311406D1 (de)	2009-05-28	Verwendung von Formkörpern
DE60107179D1 (de)	2004-12-23	Synthese von Styrol-Isopren Kautschuk
DE60332980D1 (de)	2010-07-29	Sprachsynthese
ATE499348T1 (de)	2011-03-15	Stabiler polymorph von bifeprunoxmesilat
ATE402145T1 (de)	2008-08-15	Synthese von pyrrol-2-carbonsäurenitrilen
ITMI20030352A1 (it)	2004-08-28	Metodo per la sintesi di metiltriossorenio.
DE602004007010D1 (de)	2007-07-26	Bereitstellung von lokalen oszillatorsignalen
DE60138758D1 (de)	2009-07-02	Synthese von chlorierten pyrimidinen
ATE374742T1 (de)	2007-10-15	Synthese von 2-chlormethyl-6- methylbenzoesäureestern
ATE410417T1 (de)	2008-10-15	Kristallmodifikationen von triazinylaminostilbenen
DE50307920D1 (de)	2007-09-27	Wasser-in-Öl-Cremes von Organo-Siliciumverbindungen